cladribine has been researched along with Neutropenia in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (45.24) | 18.2507 |
| 2000's | 13 (30.95) | 29.6817 |
| 2010's | 8 (19.05) | 24.3611 |
| 2020's | 2 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Araujo, C; Artifoni, M; Cohen-Aubart, F; de Menthon, M; Donadieu, J; Dromer, C; Fontenoy, AM; Genereau, T; Guillevin, L; Hamidou, M; Haroche, J; Hermine, O; Jullien, D; Kahn, JE; Lorillon, G; Maillard, H; Néel, A; Tazi, A; Tessoulin, B | 1 |
| Alfieri, G; Annunziata, M; Cerillo, I; Florio, C; Guarcello, G; Improta, G; Iorio, WD; Maniscalco, GT; Ranieri, A; Renna, R | 1 |
| Dahm, AEA; Dybedal, I; Habberstad, AH; Randen, U; Spetalen, S; Tjønnfjord, GE; Tran, HTT | 1 |
| Lv, T; Tian, X; Wang, L; Xu, J; Yuan, G | 1 |
| Attias, D; Ganzel, C; Gatt, M; Goldschmidt, N; Polliack, A; Tadmor, T | 1 |
| Delforge, M; Dierickx, D; Janssens, A; Tousseyn, T; Vandenberghe, P; Vergote, V; Verhoef, G; Wolter, P | 1 |
| Cheng, J; Lamy, T; Loughran, TP; Malysz, J; Ochmann, M; Talamo, G | 1 |
| Duan, MH; Feng, J; Han, X; Li, J; Tian, LP; Yang, C; Zhang, L; Zhang, M; Zhang, W; Zhang, Y; Zhou, DB | 1 |
| Braun, JT; Freter, CE; Lionberger, JM; Petruska, PJ; Ramlal, R; Schoen, MW; Woelich, SK | 1 |
| Bargetzi, M; Heim, D; Hess, U; Leoncini, L; Meyer-Monard, S; Rufener, B; Schmitz, SF; Solenthaler, M; Tobler, A; Zenhäusern, R | 1 |
| Allez, M; Amiot, A; Bouhnik, Y; Fieschi, C; Galicier, L; Gornet, JM; Joly, F; Lémann, M; Oksenhendler, E; Treton, X | 1 |
| Błoński, JZ; Dwilewicz-Trojaczek, J; Góra-Tybor, J; Kasznicki, M; Robak, T; Stella-Hołowiecka, B; Wołowiec, D | 1 |
| Di Raimondo, F; Ferrajoli, A; Keating, MJ; Lerner, S; Montillo, M; Morra, E; O'Brien, S; Tedeschi, A | 1 |
| Binda, BJ; Bow, EJ; Doucette, KE; Embil, JM; Galbraith, PA; Rendina, A | 1 |
| Chizuka, A; Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Tajima, K; Takaue, Y; Taniguchi, S; Usubuchi, N | 1 |
| Alinari, L; Baccarani, M; Gabriele, A; Marchi, E; Musuraca, G; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Daugherty, CK; Huo, D; Janisch, L; Larson, RA; Odenike, OM; Ratain, MJ; Sobecks, RM; Zimmerman, TM | 1 |
| Błoński, JZ; Chojnowski, K; Kasznicki, M; Robak, T; Szmigielska-Kapłon, A | 1 |
| Ishigatsubo, Y; Kanamori, H; Sakai, R; Sakamoto, H; Yamazaki, E | 1 |
| Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszynska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Jamroziak, K; Kasznicki, M; Kloczko, J; Konopka, L; Kowal, M; Kuliczkowski, K; Robak, T; Skotnicki, AB; Stella-Holowiecka, B; Sulek, K; Tomaszewska, A; Warzocha, K; Zawilska, K | 1 |
| Bauer, F; Beham-Schmid, C; Brezinschek, R; Jaeger, G; Mannhalter, C; Neumeister, P | 1 |
| Ciesielski, D; Grieb, P; Hellmann, A; Zaucha, JM | 1 |
| Heldal, D; Juliusson, G; Lenkei, R; Liliemark, J; Tjønnfjord, G | 1 |
| Ellison, D; Emanuele, S; Kosty, M; Koziol, J; Piro, L; Saven, A | 1 |
| Albertioni, F; Evensen, SA; Hedenus, M; Heldal, D; Hippe, E; Juliusson, G; Malm, C; Stolt, CM; Tjønnfjord, G; Wallman, K | 1 |
| Alexanian, R; Delasalle, KB; Dimopoulos, MA; Keating, M; Weber, D | 1 |
| Andreeff, M; Beran, M; Estey, E; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Pierce, S; Robertson, B | 1 |
| Kobayashi, K; O'Brien, SM; Ratain, MJ; Schilsky, RL; Vogelzang, NJ; Vokes, EE | 1 |
| Delannoy, A; Doyen, C; Ferrant, A; Martiat, P; Michaux, JL; Montfort, L; Sokal, G | 1 |
| Bosly, A; Delannoy, A; Ferrant, A; Martiat, P; Michaux, JL; Zenebergh, A | 1 |
| Cheung, WK; Gollard, R; Johannsen, T; Kosty, M; Miller, WE; Moyer, M; Piro, LD; Rose, E; Saven, A; Smith, I | 1 |
| Hellmann, A; Lewandowski, K; Pawlik, H; Siedlewicz, A; Zaucha, JM | 1 |
| Baldinger, C; Bettelheim, P; Chott, A; Fridrik, MA; Jäger, G; Krieger, O | 1 |
| Hoffman, MA; Janson, D; Rai, KR; Rose, E | 1 |
| Hotta, T; Kinoshita, T; Kobayashi, Y; Kozuru, M; Narabayashi, M; Ogura, M; Ohashi, Y; Suzuki, R; Tobinai, K; Uike, N | 1 |
| Delmer, A; Legrand, O; Marie, JP; Vekhoff, A; Zittoun, R | 1 |
| Betticher, DC; Cerny, T; Egger, T; Fey, MF; Hess, U; Hsu Schmitz, SF; Pugin, P; Ratschiller, D; Stalder, M; von Rohr, A | 1 |
| Błasińska-Morawiec, M; Błoński, J; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Hansz, J; Hałaburda, K; Hellmann, A; Hołowiecki, J; Konopka, L; Kotlarek-Haus, S; Potoczek, S; Robak, T; Skotnicki, AB; Urasiński, I; Zdziarska, B | 1 |
| Bocchia, M; Lauria, F; Marotta, G; Raspadori, D; Rondelli, D; Zinzani, PL | 1 |
| Adusumalli, J; Burian, C; Koziol, JA; Saven, A | 1 |
| Dmoszyńska, A; Kowal, M; Lech-Marańda, E; Robak, T; Wrzesień-Kuś, A | 1 |
| Blasińska-Morawiec, M; Bloński, JZ; Ceglarek, B; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Grieb, P; Hellmann, A; Kasznicki, M; Konopka, L; Kotlarek-Haus, S; Krykowski, E; Maj, S; Mrugala-Spiewak, H; Nowak, W; Potoczek, S; Robak, T; Skotnicki, AB; Urasiński, I; Zdziarska, B | 1 |
1 review(s) available for cladribine and Neutropenia
| Article | Year |
|---|---|
Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review.
Topics: Adult; Age of Onset; Aged, 80 and over; Antimetabolites; Cladribine; Dose-Response Relationship, Drug; Female; France; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Proportional Hazards Models; Remission Induction; Retrospective Studies; Sepsis; Virus Diseases | 2020 |
18 trial(s) available for cladribine and Neutropenia
| Article | Year |
|---|---|
Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neutropenia; Remission Induction; Treatment Outcome; Young Adult | 2009 |
Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Opportunistic Infections; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2002 |
Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukopenia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2003 |
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Administration Schedule; Fatigue; Feasibility Studies; Female; Gemcitabine; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Thrombocytopenia | 2004 |
Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Etoposide; Female; Humans; Infections; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome | 2005 |
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Neutropenia; Remission Induction | 2006 |
2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Anemia; Cladribine; Disease-Free Survival; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Recurrence; Survival Rate; Thrombocytopenia; Time Factors | 1995 |
Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.
Topics: Adult; Aged; beta 2-Microglobulin; Bone Marrow; Cladribine; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Hairy Cell; Male; Middle Aged; Neutropenia; Norway; Remission Induction | 1995 |
Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors.
Topics: Adult; Aged; Cladribine; Humans; Middle Aged; Neutropenia; Prognosis; Recurrence; Remission Induction; Survival Rate; Waldenstrom Macroglobulinemia | 1995 |
A phase I study of intermittent infusion cladribine in patients with solid tumors.
Topics: Adult; Aged; Blindness; Carcinoma, Non-Small-Cell Lung; Cladribine; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1994 |
2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukaemia.
Topics: Aged; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Salvage Therapy; Seizures; Survival Rate; Thrombocytopenia; Treatment Outcome | 1994 |
2-Chlorodeoxyadenosine therapy in Waldenstrom's macroglobulinaemia.
Topics: Aged; Aged, 80 and over; Cladribine; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Outcome; Waldenstrom Macroglobulinemia | 1994 |
First-line treatment of Waldenström's disease with cladribine. Arbeitsgemeinschaft Medikamentöse Tumortherapie.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Humans; Interferon Type I; Male; Middle Aged; Neutropenia; Prospective Studies; Recombinant Proteins; Remission Induction; Waldenstrom Macroglobulinemia | 1997 |
Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group.
Topics: Aged; Antineoplastic Agents; Cladribine; Female; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neutropenia; Thrombocytopenia | 1997 |
Cladribine (2-CDA) given as subcutaneous bolus injections is active in pretreated Waldenström's macroglobulinaemia. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adult; Aged; Aged, 80 and over; Cladribine; Female; Humans; Immunosuppressive Agents; Injections, Intradermal; Male; Middle Aged; Neutropenia; Opportunistic Infections; Thrombocytopenia; Treatment Outcome; Waldenstrom Macroglobulinemia | 1997 |
Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cladribine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infection Control; Interferon-alpha; Leukemia, Hairy Cell; Lymphopenia; Male; Middle Aged; Neutropenia; Pentostatin; Remission Induction; Treatment Outcome | 1999 |
Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Drug Administration Schedule; Female; Fever; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leukemia, Hairy Cell; Male; Middle Aged; Neutropenia; Recombinant Proteins | 1999 |
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neutropenia; Poland; Prednisone; Prospective Studies; Remission Induction; Survival Rate; Thrombocytopenia; Treatment Outcome | 2000 |
23 other study(ies) available for cladribine and Neutropenia
| Article | Year |
|---|---|
Remission of early persistent cladribine-induced neutropenia after filgrastim therapy in a patient with Relapsing - Remitting Multiple Sclerosis.
Topics: Cladribine; Filgrastim; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neutropenia; Recombinant Proteins | 2020 |
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Cladribine; Disease Progression; Fatal Outcome; Humans; Janus Kinase 2; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Leukopenia; Male; Neutropenia; Oral Ulcer; Polycythemia Vera; Primary Myelofibrosis; Splenomegaly; Thrombocytopenia | 2018 |
Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cladribine; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Recurrence; Survival Rate; Treatment Outcome | 2019 |
Pegfilgrastim prophylaxis for cladribine-induced neutropenia in patients with hairy-cell leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Cohort Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Hairy Cell; Leukocyte Count; Male; Middle Aged; Neutropenia; Neutrophils; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Young Adult | 2014 |
Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.
Topics: Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cladribine; Combined Modality Therapy; Compassionate Use Trials; Drug Resistance, Neoplasm; Humans; Imidazoles; Leukemia, Hairy Cell; Male; Middle Aged; Molecular Targeted Therapy; Mutation, Missense; Neoplasm Proteins; Neutropenia; Oximes; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pulmonary Aspergillosis; Remission Induction; Rituximab; Salvage Therapy; Splenectomy | 2014 |
Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Causality; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Large Granular Lymphocytic; Male; Melphalan; Methotrexate; Middle Aged; Multiple Myeloma; Neutropenia; Paraproteinemias; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Registries; Retrospective Studies; Thalidomide | 2014 |
[Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Young Adult | 2016 |
Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Exanthema; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid; Male; Middle Aged; Mucositis; Neutropenia; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
High frequency of fatal haemophagocytic lymphohistiocytosis syndrome in enteropathy-associated T cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease Progression; Disease-Free Survival; Enteropathy-Associated T-Cell Lymphoma; Female; Humans; Kaplan-Meier Estimate; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Neutropenia; Purine Nucleotides; Retrospective Studies | 2012 |
Disseminated zygomycosis: a rare cause of infection in patients with hematologic malignancies.
Topics: Amphotericin B; Antineoplastic Agents; Cladribine; Deoxycholic Acid; Drug Combinations; Fatal Outcome; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neutropenia; Zygomycosis | 2003 |
Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Busulfan; Child; Child, Preschool; Cladribine; Female; Fever; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Transplantation Conditioning; Vidarabine | 2004 |
Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neutropenia; Treatment Outcome | 2004 |
[Successful treatment with cladribine for hypoplastic hairy cell leukemia after long-term neutropenia].
Topics: Adult; Antineoplastic Agents; Cladribine; Female; Humans; Injections, Intravenous; Leukemia, Hairy Cell; Neutropenia; Remission Induction; Time Factors | 2005 |
Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine.
Topics: Adult; Alemtuzumab; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Transfusion; Cladribine; Cyclophosphamide; Doxorubicin; Female; Humans; Liver Neoplasms; Lymphoma, T-Cell; Neutropenia; Prednisolone; Receptors, Antigen, T-Cell, gamma-delta; Recurrence; Remission Induction; Rituximab; Splenic Neoplasms; Vincristine | 2008 |
2-Chloro-2'-deoxyadenosine (2-CdA) treatment in a patient with Waldenström's macroglobulinaemia complicated by severe neutrocytopenia.
Topics: Aged; Animals; Cladribine; Humans; Immunosuppressive Agents; Male; Mice; Neutropenia; Waldenstrom Macroglobulinemia | 1994 |
Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: predictive factors and effects of granulocyte-macrophage colony-stimulating factor.
Topics: Cladribine; Female; Fever; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neutropenia; Risk Factors; T-Lymphocyte Subsets | 1995 |
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neutropenia; Remission Induction; Thrombocytopenia; Vidarabine | 1994 |
Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biological Availability; Cladribine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 1996 |
2-Chlorodeoxyadenosine treatment in the Sezary syndrome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cladribine; Female; Humans; Infections; Male; Middle Aged; Neutropenia; Sezary Syndrome; Thrombocytopenia; Treatment Failure | 1997 |
Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neutropenia; Phenotype; Recurrence; Remission Induction | 1997 |
Treatment of hairy cell leukaemia (HCL) with 2-chlorodeoxyadenosine (2-CdA): identification of parameters predictive of adverse effects.
Topics: Antineoplastic Agents; Blood Transfusion; Cladribine; Female; Humans; Interferons; Leukemia, Hairy Cell; Male; Neutropenia | 1997 |
2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Cohort Studies; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Neutropenia; Poland; Survival Rate; Thrombocytopenia; Time Factors; Treatment Outcome | 1999 |
Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2000 |